Tyra Biosciences, Inc. (TYRA) NASDAQ
28.66
-1.73(-5.69%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
28.66
-1.73(-5.69%)
Currency In USD
Address
2656 State Street
Carlsbad, CA 92008
United States of America (the)
Phone
619 728 4760
Website
Sector
Healthcare
Industry
Biotechnology
Employees
60
First IPO Date
September 15, 2021
| Name | Title | Pay | Year Born |
| Todd Harris | Co-Founder, CEO, President & Director | 998,960 | 1979 |
| Ronald V. Swanson | Chief Scientific Officer | 536,188 | 1963 |
| Bhavesh Ashar | Chief Operating Officer | 551,017 | 1969 |
| Ali D. Fawaz | General Counsel & Secretary | 629,230 | N/A |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 737,643 | 1975 |
| Alan Fuhrman | Chief Financial Officer | 763,093 | 1957 |
| Douglas Warner | Chief Medical Officer | 764,683 | 1972 |
| Ralph William Charlton | Senior Vice President of Clinical Development | 0 | 1971 |
| Erik Goluboff | Senior Vice President of Clinical Development | 0 | N/A |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 0 | 1986 |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy | 0 | N/A |
| Robert L. Hudkins | Chief Technology Officer | 0 | 1955 |
| Liz Pagano | Chief Human Resources Officer | 0 | N/A |
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.